Efficacy Study of Tempol to Prevent Hair Loss From Radiotherapy to the Brain

Recruiting

Phase 2

Efficacy Study of Tempol to Prevent Hair Loss From Radiotherapy to the Brain

Sponsor:

Mitos Pharmaceuticals

Code:

NCT00801086

Conditions

Alopecia

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

7% (w/v) Tempol alcohol-based gel (MTS-01)

alcohol-based gel

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information